Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis
Telesis Bio and Beckman Coulter Life Sciences have announced a collaboration to revolutionize DNA and mRNA synthesis. The partnership aims to create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesis of DNA. This innovative approach combines Telesis Bio's Gibson SOLA enzymatic reagent platform with Beckman Coulter Life Sciences' automation expertise.
The collaboration integrates Telesis Bio's Gibson SOLA Enzymatic Synthesis technology with the new Biomek Echo One System from Beckman Coulter Life Sciences. This integration ensures rapid, reliable, and highly scalable production of extremely high-fidelity DNA, empowering researchers to achieve greater productivity and innovation in various discovery applications.
The partnership aims to establish local and on-premise DNA foundries that function as digital-to-biologic converters, delivering DNA or mRNA as fast as overnight. This collaboration is expected to set a new standard for on-premises biofoundries and drive forward the next generation of therapeutic and diagnostic advancements.
Telesis Bio e Beckman Coulter Life Sciences hanno annunciato una collaborazione per rivoluzionare la sintesi di DNA e mRNA. L'obiettivo della partnership è quello di creare biofabbriche efficienti e scalabili, fornendo soluzioni per una sintesi sostenibile e rapida di DNA in sede. Questo approccio innovativo unisce la piattaforma di reagenti enzimatici Gibson SOLA di Telesis Bio con l'expertise in automazione di Beckman Coulter Life Sciences.
La collaborazione integra la tecnologia di sintesi enzimatica Gibson SOLA di Telesis Bio con il nuovo Biomek Echo One System di Beckman Coulter Life Sciences. Questa integrazione garantisce una produzione rapida, affidabile e altamente scalabile di DNA ad alta fedeltà, permettendo ai ricercatori di raggiungere maggiore produttività e innovazione in diverse applicazioni di scoperta.
La partnership mira a stabilire fabbriche di DNA locali e in sede che fungano da convertitori digitali a biologici, fornendo DNA o mRNA in tempi rapidi, anche durante la notte. Si prevede che questa collaborazione stabilisca un nuovo standard per le biofabbriche in sede e faccia progredire la prossima generazione di avanzamenti terapeutici e diagnostici.
Telesis Bio y Beckman Coulter Life Sciences han anunciado una colaboración para revolucionar la síntesis de ADN y ARN mensajero. La asociación tiene como objetivo crear biofábricas eficientes y escalables, ofreciendo soluciones para una sintesis sostenible y rápida de ADN en el lugar. Este enfoque innovador combina la plataforma de reactivos enzimáticos Gibson SOLA de Telesis Bio con la experiencia en automatización de Beckman Coulter Life Sciences.
La colaboración integra la tecnología de síntesis enzimática Gibson SOLA de Telesis Bio con el nuevo Biomek Echo One System de Beckman Coulter Life Sciences. Esta integración asegura una producción rápida, confiable y altamente escalable de ADN de alta fidelidad, empoderando a los investigadores para lograr una mayor productividad e innovación en diversas aplicaciones de descubrimiento.
La asociación tiene como objetivo establecer fábricas de ADN locales y en el lugar que funcionen como convertidores de digital a biológico, proporcionando ADN o ARN mensajero tan rápido como durante la noche. Se espera que esta colaboración establezca un nuevo estándar para las biofábricas en el lugar y avance la próxima generación de innovaciones terapéuticas y diagnósticas.
Telesis Bio와 Beckman Coulter Life Sciences는 DNA 및 mRNA 합성을 혁신하기 위한 협업을 발표했습니다. 이 파트너십의 목표는 효율적이고 확장 가능한 바이오 팹을 만들어 지속 가능하고 신속한 현장 DNA 합성 솔루션을 제공하는 것입니다. 이 혁신적인 접근은 Telesis Bio의 Gibson SOLA 효소 시약 플랫폼과 Beckman Coulter Life Sciences의 자동화 전문성을 결합합니다.
이번 협업은 Telesis Bio의 Gibson SOLA 효소 합성 기술을 Beckman Coulter Life Sciences의 새로운 Biomek Echo One System과 통합합니다. 이 통합은 매우 높은 정확도의 DNA를 신속하고 신뢰할 수 있으며 대규모로 생산할 수 있도록 하여 연구자들이 다양한 발견 응용 분야에서 더 높은 생산성과 혁신을 달성할 수 있도록 합니다.
파트너십은 디지털에서 생물로 변환하는 역할을 하는 현지 및 현장 DNA 팹을 구축하는 것을 목표로 하여 ADN이나 mRNA를 하룻밤 만에 제공할 수 있습니다. 이 협업은 현장 바이오 팹의 새로운 표준을 설정하고 다음 세대의 치료 및 진단 발전을 촉진할 것으로 기대됩니다.
Telesis Bio et Beckman Coulter Life Sciences ont annoncé une collaboration pour révolutionner la synthèse d'ADN et d'ARNm. Cette partenariat vise à créer des biofabriques efficaces et évolutives, fournissant des solutions pour une synthèse durable et rapide d'ADN sur site. Cette approche innovante combine la plateforme de réactifs enzymatiques Gibson SOLA de Telesis Bio avec l'expertise en automatisation de Beckman Coulter Life Sciences.
La collaboration intègre la technologie de synthèse enzymatique Gibson SOLA de Telesis Bio avec le nouveau Biomek Echo One System de Beckman Coulter Life Sciences. Cette intégration garantit une production rapide, fiable et hautement évolutive d'ADN à très haute fidélité, permettant aux chercheurs d'atteindre une plus grande productivité et innovation dans diverses applications de découverte.
Le partenariat vise à établir des usines d'ADN locales et sur site qui fonctionnent comme des convertisseurs numériques vers biologiques, livrant de l'ADN ou de l'ARNm aussi rapidement que le lendemain. Cette collaboration devrait établir une nouvelle norme pour les biofabriques sur site et faire progresser la prochaine génération d'avancées thérapeutiques et diagnostiques.
Telesis Bio und Beckman Coulter Life Sciences haben eine Kollaboration zur Revolutionierung der DNA- und mRNA-Synthese angekündigt. Ziel dieser Partnerschaft ist es, effiziente und skalierbare Biofabriken zu schaffen, um Lösungen für die nachhaltige und schnelle Synthese von DNA vor Ort bereitzustellen. Dieser innovative Ansatz kombiniert die enzymatische Reagenzplattform Gibson SOLA von Telesis Bio mit der Automatisierungsexpertise von Beckman Coulter Life Sciences.
Die Zusammenarbeit integriert die Technologie der enzymatischen Synthese von Telesis Bio mit dem neuen Biomek Echo One System von Beckman Coulter Life Sciences. Diese Integration gewährleistet eine schnelle, zuverlässige und hochskalierbare Produktion von extrem hochgenauem DNA, wodurch Forscher in der Lage sind, eine höhere Produktivität und Innovation in verschiedenen Entdeckungsanwendungen zu erreichen.
Die Partnerschaft hat zum Ziel, lokale und vor Ort befindliche DNA-Fabriken zu etablieren, die als digitale zu biologischen Konverter fungieren und DNA oder mRNA so schnell wie über Nacht liefern. Es wird erwartet, dass diese Zusammenarbeit einen neuen Standard für ortsansässige Biofabriken setzt und die nächste Generation therapeutischer und diagnostischer Fortschritte vorantreibt.
- Integration of Gibson SOLA Enzymatic Synthesis technology with Biomek Echo One System for improved DNA synthesis
- Potential for rapid, overnight delivery of DNA or mRNA through on-premise biofoundries
- Open solution allowing incorporation of constructs from other providers compatible with Gibson SOLA
- Partnership aims to improve productivity and innovation in discovery applications
- None.
Insights
This collaboration between Telesis Bio and Beckman Coulter Life Sciences represents a significant advancement in DNA and mRNA synthesis technology. The integration of Telesis Bio's Gibson SOLA Enzymatic Synthesis with Beckman Coulter's Biomek Echo One System creates a powerful, automated biofoundry solution. Key benefits include:
- High-fidelity DNA production with rapid turnaround (potentially overnight)
- Scalable, on-premises synthesis capabilities
- Non-toxic processes, improving lab safety
- Open platform compatibility, enhancing flexibility
This innovation could accelerate research in therapeutics and diagnostics by providing faster access to custom DNA and mRNA constructs. For Telesis Bio (
This partnership has the potential to disrupt the synthetic biology market, which is projected to reach
- Democratization of DNA/mRNA synthesis, enabling smaller labs to perform in-house production
- Potential shift from centralized to distributed manufacturing model in biotech
- Increased competition for existing DNA synthesis service providers
- Acceleration of research timelines across various biotech applications
For Telesis Bio, a micro-cap company, this collaboration could be transformative. It provides access to Beckman Coulter's extensive customer base and distribution channels. If successful, we might see significant revenue growth and market share expansion for Telesis Bio in the coming years. Investors should monitor adoption rates, revenue growth and any expansion of similar partnerships to gauge the long-term impact on Telesis Bio's valuation.
Innovation Delivers High-Fidelity, Scalable, Non-Toxic On-Premises Biofoundry Capabilities
SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- A new partnership between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, will create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesis of DNA. This innovative approach enabled by Telesis Bio’s Gibson SOLA enzymatic reagent platform running on Beckman Coulter Life Sciences automation to ensures rapid, reliable, and highly scalable production of extremely high-fidelity DNA, empowering researchers to achieve greater productivity and innovation in a wide array of discovery applications.
The collaboration integrates Telesis Bio’s Gibson SOLA Enzymatic Synthesis technology with the new Biomek Echo One System from Beckman Coulter Life Sciences. It also delivers an open solution to the market, allowing the incorporation of constructs from other providers compatible with Gibson SOLA, further expanding the technology’s flexibility to synthesize unique or challenging biology.
“Gibson SOLA Enzymatic DNA Synthesis, in partnership with Beckman Coulter Life Sciences, is set to revolutionize synthetic biology through next-generation synthesis technology. Drawing parallels to the automotive industry’s success with distributed manufacturing, we aim to establish local and on-premise DNA foundries that function as digital-to-biologic converters delivering DNA or mRNA as fast as overnight. By expanding our network of compatible partners, we continue to drive forward the capabilities of Gibson SOLA" said Dan Gibson, Co-Founder and CTO.
Eric Esser, CEO of Telesis Bio, commented on the collaboration: "This partnership marks a significant milestone in advancing synthetic biology. By integrating Gibson SOLA's high-fidelity, scalable, and non-toxic DNA synthesis capabilities with Beckman Coulter Life Sciences automation expertise, we are setting a new standard for on-premises biofoundries. This collaboration empowers researchers to greatly improve productivity through faster, more reliable, and innovative solutions, driving forward the next generation of therapeutic and diagnostic advancements."
“This partnership with Telesis Bio delivers on our promise to be a trusted and preferred laboratory partner, to more quickly and accurately enable breakthrough research discoveries,” said Ewan Grant, Senior Director of the Biotech Workflow Solutions Business Unit at Beckman Coulter Life Sciences. “This innovation brings exciting new possibilities to DNA and mRNA synthesis workflows, unleashing the benefits of our new Biomek Echo One System including seamlessly executing library preparation steps such as extraction, fragmentation, ligation, normalization and pooling along with requisite actions such as centrifugation, shaking and thermal incubation in one automated method.”
About Telesis Bio
Telesis Bio is empowering scientists to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. With our revolutionary Gibson SOLA Enzymatic Synthesis platform, we are transforming the industry by providing non-toxic, high-fidelity, and scalable DNA synthesis. The Gibson SOLA platform, combined with our award-winning BioXp® systems, enables rapid, accurate, and reproducible writing of DNA and mRNA, automating and optimizing the entire synthesis, cloning, and amplification workflow. Scientists worldwide leverage our technology to accelerate the design-build-test paradigm, driving innovation in precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit www.telesisbio.com, LinkedIn & About Gibson SOLA.
About Beckman Coulter Life Sciences
With a relentless mission to empower those seeking answers to life’s important scientific questions, Beckman Coulter Life Sciences is a preferred laboratory partner providing automation and innovation solutions for Centrifugation, Flow Cytometry, Genomics, Particle Analysis, and Liquid Handling workflows. With a legacy dating back to 1935, our technologies reduce manual laboratory processes and can provide greater speed, accuracy, and advanced analytics to accelerate answers with a guiding focus to improve patient care and enable pioneering discoveries. Beckman Coulter Life Sciences is headquartered in Indianapolis, Indiana with 11 operational hubs around the world and employs approximately 2,800 associates with more than 400,000 systems installed globally. Get to know us by clicking here and by following us on LinkedIn.
Contact: Matt McCutcheon, Global External Communications Manager, mmccutcheon@beckman.com, 317-719-0557
FAQ
What is the purpose of the collaboration between Telesis Bio and Beckman Coulter Life Sciences?
How does the partnership between Telesis Bio (TBIO) and Beckman Coulter Life Sciences benefit researchers?
What is the goal of Telesis Bio (TBIO) regarding local DNA foundries?
How does the collaboration between Telesis Bio (TBIO) and Beckman Coulter Life Sciences impact synthetic biology?
